Arovella Therapeutics is an Australian biotechnology company specialised in immunoncology with a focus on the invariant natural killer T (iNKT) cell therapy platform, which was in-licensed from Imperial College London in July 2021. The platform can be combined with chimeric antigen receptors (CARs) to target blood cancers, with a potential of being an allogeneic ‘off-the-shelf’ therapy. This was followed by the in-licensing of a novel monoclonal antibody targeting a Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center in December 2021. Arovella plans to combine the DKK1-targeting technology with the iNKT cell therapy platform in the future. With recent fund-raising activity, we believe the company has sufficient funds for its development activities until CY23.
In this video, CEO Michael Baker provides an update on Arovella’s recent milestones and strategy.